DK1315694T3 - Inhibitorer af alpha-4-medieret celleadhæsion - Google Patents
Inhibitorer af alpha-4-medieret celleadhæsionInfo
- Publication number
- DK1315694T3 DK1315694T3 DK01966246T DK01966246T DK1315694T3 DK 1315694 T3 DK1315694 T3 DK 1315694T3 DK 01966246 T DK01966246 T DK 01966246T DK 01966246 T DK01966246 T DK 01966246T DK 1315694 T3 DK1315694 T3 DK 1315694T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- alpha
- cell adhesion
- mediated cell
- mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22912800P | 2000-08-31 | 2000-08-31 | |
| PCT/US2001/026594 WO2002018320A2 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1315694T3 true DK1315694T3 (da) | 2005-08-08 |
Family
ID=22859926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01966246T DK1315694T3 (da) | 2000-08-31 | 2001-08-27 | Inhibitorer af alpha-4-medieret celleadhæsion |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US7026501B2 (enExample) |
| EP (1) | EP1315694B1 (enExample) |
| JP (1) | JP3899022B2 (enExample) |
| KR (1) | KR100528049B1 (enExample) |
| CN (1) | CN1229334C (enExample) |
| AR (1) | AR034556A1 (enExample) |
| AT (1) | ATE292615T1 (enExample) |
| AU (2) | AU8677801A (enExample) |
| BR (1) | BR0113629A (enExample) |
| CA (1) | CA2418054C (enExample) |
| CZ (1) | CZ303460B6 (enExample) |
| DE (1) | DE60109943T2 (enExample) |
| DK (1) | DK1315694T3 (enExample) |
| ES (1) | ES2240509T3 (enExample) |
| HK (1) | HK1052684B (enExample) |
| HU (1) | HUP0302693A3 (enExample) |
| IL (2) | IL154305A0 (enExample) |
| MX (1) | MXPA03001837A (enExample) |
| MY (1) | MY129000A (enExample) |
| NO (1) | NO327861B1 (enExample) |
| NZ (1) | NZ524043A (enExample) |
| PL (1) | PL206656B1 (enExample) |
| PT (1) | PT1315694E (enExample) |
| RU (1) | RU2250895C2 (enExample) |
| SI (1) | SI1315694T1 (enExample) |
| TW (1) | TWI224587B (enExample) |
| WO (1) | WO2002018320A2 (enExample) |
| ZA (1) | ZA200301039B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2420040C (en) | 2000-08-18 | 2009-02-03 | Ajinomoto Co., Inc. | New phenylalanine derivatives |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| BR0209252A (pt) | 2001-04-27 | 2004-07-20 | Eisai Co Ltd | Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas |
| MY140707A (en) * | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
| US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| AU2003275589B2 (en) | 2002-10-22 | 2009-05-28 | Eisai R & D Management Co., Ltd. | 7-phenyl pyrazolopyridine compounds |
| US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
| WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| BRPI0418026A (pt) * | 2003-12-22 | 2007-04-17 | Ajinomoto Kk | derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças |
| US7410971B2 (en) | 2003-12-26 | 2008-08-12 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| US7910734B2 (en) | 2004-12-20 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
| CA2610800A1 (en) | 2005-06-09 | 2006-12-14 | Ucb Pharma, S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
| CN101360711A (zh) * | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-苯丙氨酸衍生物及其作为整联蛋白拮抗剂的用途 |
| WO2007089335A2 (en) * | 2005-12-29 | 2007-08-09 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
| US7897763B2 (en) | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
| US8808698B2 (en) * | 2006-02-03 | 2014-08-19 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
| US20090203663A1 (en) * | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| KR20080104343A (ko) * | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
| RU2493156C2 (ru) * | 2007-08-24 | 2013-09-20 | Лексикон Фармасьютикалз, Инк. | Способы получения соединений на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина |
| MY152687A (en) | 2008-04-15 | 2014-10-31 | Eisai R&D Man Co Ltd | 3-phenylpyrazolo[5,1-b]thiazole compound |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| MX2012004707A (es) | 2009-10-21 | 2012-06-08 | Glaxo Group Ltd | Proceso para la preparacion de un derivado de fenilalanina. |
| BR112012017014B1 (pt) | 2010-01-11 | 2021-07-20 | Biogen Ma Inc | Métodos para detecção de anticorpos de vírus jc |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| HUE061244T2 (hu) | 2011-05-31 | 2023-06-28 | Biogen Ma Inc | A PML kockázat értékelésének módszere |
| WO2013126595A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye And Ear Infirmary | Methods for treating corneal and conjunctival inflammation and inflammatory disorders |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHOD FOR ASSESSING A PML RISK |
| WO2018085552A1 (en) * | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK148576A (da) | 1975-04-18 | 1976-10-19 | Boehringer Mannheim Gmbh | Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling |
| BR9407933A (pt) | 1993-11-01 | 1996-11-26 | Japat Ltd | Antagonistas de receptores de endotelina |
| MX9604368A (es) | 1994-03-28 | 1997-12-31 | Ciba Geigy Japan Ltd | Antagonistas de receptores de endotelina. |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| ATE318841T1 (de) | 1997-05-29 | 2006-03-15 | Merck & Co Inc | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
| WO1998054207A1 (en) | 1997-05-30 | 1998-12-03 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
| ATE249421T1 (de) | 1997-06-23 | 2003-09-15 | Tanabe Seiyaku Co | Inhibitoren der alpha4-beta1 vermittelten zelladhäsion |
| PL338373A1 (en) | 1997-07-31 | 2000-10-23 | Elan Pharm Inc | Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4 |
| AU8661298A (en) | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| KR20010022414A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물 |
| BR9811594A (pt) | 1997-07-31 | 2000-09-05 | Elan Pharm Inc | Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4 |
| IL133640A0 (en) | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| CN1265675A (zh) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 抑制由vla－4介导的白细胞粘着的苄基化合物 |
| IL133641A0 (en) | 1997-07-31 | 2001-04-30 | Elan Pharm Inc | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| KR100554815B1 (ko) * | 1997-08-22 | 2006-02-22 | 에프. 호프만-라 로슈 아게 | 엔-아로일페닐알라닌 유도체 |
| ATE260243T1 (de) | 1997-08-22 | 2004-03-15 | Hoffmann La Roche | N-aroylphenylalaninderivate |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
| ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
| JP2001523711A (ja) | 1997-11-24 | 2001-11-27 | メルク エンド カムパニー インコーポレーテッド | 細胞接着阻害薬としての環状アミノ酸誘導体 |
| US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| JP2002504534A (ja) | 1998-02-26 | 2002-02-12 | セルテック・セラピューティクス・リミテッド | α４インテグリンの阻害剤としてのフェニルアラニン誘導体 |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1999064395A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| JP2003524614A (ja) | 1998-12-22 | 2003-08-19 | 田辺製薬株式会社 | α４β１媒介細胞接着のインヒビター |
| GB2354440A (en) | 1999-07-20 | 2001-03-28 | Merck & Co Inc | Aryl amides as cell adhesion inhibitors |
| AU6903200A (en) | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
| AU6909300A (en) | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| EP1214292B1 (en) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
| EP1315696A1 (en) | 2000-08-31 | 2003-06-04 | Eli Lilly And Company | Acetylenic sulfonamide derivatives |
-
2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en not_active Ceased
- 2001-08-27 HK HK03105043.3A patent/HK1052684B/en not_active IP Right Cessation
- 2001-08-27 ES ES01966246T patent/ES2240509T3/es not_active Expired - Lifetime
- 2001-08-27 DE DE60109943T patent/DE60109943T2/de not_active Expired - Lifetime
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/xx unknown
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/pt active Search and Examination
- 2001-08-27 PT PT01966246T patent/PT1315694E/pt unknown
- 2001-08-27 SI SI200130351T patent/SI1315694T1/xx unknown
- 2001-08-27 PL PL365668A patent/PL206656B1/pl unknown
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/ru not_active IP Right Cessation
- 2001-08-27 AU AU8677801A patent/AU8677801A/xx active Pending
- 2001-08-27 IL IL15430501A patent/IL154305A0/xx unknown
- 2001-08-27 DK DK01966246T patent/DK1315694T3/da active
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/ko not_active Expired - Fee Related
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/cs not_active IP Right Cessation
- 2001-08-27 CN CNB018149871A patent/CN1229334C/zh not_active Expired - Fee Related
- 2001-08-27 AT AT01966246T patent/ATE292615T1/de active
- 2001-08-27 EP EP01966246A patent/EP1315694B1/en not_active Expired - Lifetime
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/es active IP Right Grant
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/hu unknown
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/ja not_active Expired - Fee Related
- 2001-08-31 TW TW090121581A patent/TWI224587B/zh not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/es active IP Right Grant
-
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/no not_active IP Right Cessation
-
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
-
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
-
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
-
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1049662T3 (da) | Inhibitorer af alpha4-medieret celleadhæsion | |
| DK1501508T3 (da) | Inhibitorer af histondeatylase | |
| DK1183033T3 (da) | Pyrrolotriazininhibitorer af kinaser | |
| DK1307263T3 (da) | Hidtil ukendt anvendelse af lipaseinhibitorer | |
| DK1064298T3 (da) | Inhibitorer af caspaser | |
| NO20030885L (no) | Inhibitorer av <alfa>4 styrt celleadhesjon | |
| IS6289A (is) | thríhringja hindrar af poly (ADP-ribosa) polymerösum | |
| DK1077943T3 (da) | Heterocykliske inhibitorer af p38 | |
| DK1341779T3 (da) | Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion | |
| EE200300088A (et) | Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena | |
| AR028253A1 (es) | Inhibidores de la glucogeno fosforilasa | |
| DE60008527D1 (de) | Zellproliferation inhibitoren | |
| DK1438306T3 (da) | Derivater af UK-2A | |
| DK1686113T3 (da) | Inhibitorer af aspartylprotease | |
| DK1362050T3 (da) | Pyrimidinderivater til inhibition af celleproliferation | |
| DE60131992D1 (de) | Pfropfcopolymere enthaltende klebstoffe | |
| NO20024997D0 (no) | 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer | |
| DK1470732T3 (da) | Fremskaffelse af lokaliseringsinformation | |
| DK1458447T3 (da) | Kombination af cytokrom-p450-beroende proteasinhibitorer | |
| DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
| DK1144425T3 (da) | Derivater af monosaccharider som celleadhæsionsinhibitorer | |
| NO20014243L (no) | Dihetero-substituerte metalloproteaseinhibitorer | |
| ATE277023T1 (de) | Indanderivate und ihre verwendung als zelladhäsionsinihibitoren | |
| IS6215A (is) | Að mestu leyti kristallað form af melagatrani | |
| ATE411995T1 (de) | Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion |